Related Experiment Video
Updated: Aug 22, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
All Platinum(II) Ions Are Equal, but Some React Differently: Insights Into the Biomolecular Reactivity of
Andrea Cucchiaro1, Monika Cziferszky1
1Institute of Pharmacy, Pharmaceutical Chemistry, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80/82, Innsbruck A-6020, Austria, uibk.ac.at.
Abstract:
Platinum-based anticancer agents are widely used in cancer therapy due to their efficacy in killing cancer cells through interactions with the DNA. However, their clinical application is limited by severe side effects and the development of drug resistance, which have been related to their lack of specificity and mechanism of action. To overcome these challenges, novel platinum(II) complexes, K[Pt(Butene-ASA)Cl3] (Compound 1) and [Pt(L-Ala)(Butene-ASA)Cl] (Compound 2), were previously synthesized and characterized. Particularly, Compound 2 showed cytotoxic activity comparable to that of cisplatin (DDP) against all tested cancer cell lines in a previous study. The current investigation employed electrospray ionization mass spectrometry (ESI-MS) to analyze the interactions of these complexes with model biomolecules, including an oligonucleotide (8mer), peptide (Angiotensin I, AT1), and protein (Cytochrome c, CytC). DDP and oxaliplatin (OxPt) were used as reference substances. Tandem mass spectrometry (MS/MS) and UV-Vis spectroscopy enabled the identification of the platination sites on the model biomolecules. Compound 2 demonstrated lower reactivity toward DNA than DDP, while both compounds 1 and 2 exhibited a significant shift in reactivity toward peptides and proteins, particularly compared to DDP and OxPt. The results suggest that Zeise's salt derivatives may preferentially target peptides and proteins rather than DNA, which could provide a novel mechanism of action for platinum-based anticancer agents. These findings expand the understanding of platinum(II) complex reactivity and highlight their potential for developing alternative therapeutic strategies aimed at overcoming the limitations of traditional platinum-based drugs.
Insights
Novel platinum(II) complexes show potential as anticancer agents by targeting peptides and proteins, not DNA. This offers a new mechanism to overcome resistance and side effects associated with traditional platinum drugs.
Area of Science:
- Coordination Chemistry
- Medicinal Chemistry
- Biochemistry
Background:
- Platinum-based drugs are mainstays in cancer therapy but face limitations like severe side effects and drug resistance.
- These limitations stem from platinum agents' lack of specificity and poorly understood mechanisms of action.
- Novel platinum(II) complexes offer potential alternatives to overcome current therapeutic challenges.
Purpose of the Study:
- To investigate the biomolecular interactions of novel platinum(II) complexes, K[Pt(Butene-ASA)Cl3] (Compound 1) and [Pt(L-Ala)(Butene-ASA)Cl] (Compound 2).
- To compare the reactivity of these novel complexes with cisplatin (DDP) and oxaliplatin (OxPt) towards DNA, peptides, and proteins.
- To elucidate the potential novel mechanisms of action for these platinum(II) complexes in cancer therapy.
Main Methods:
- Electrospray ionization mass spectrometry (ESI-MS) was used to analyze interactions with biomolecules.
- Tandem mass spectrometry (MS/MS) and UV-Vis spectroscopy identified platination sites.
- Model biomolecules included an oligonucleotide (8mer), Angiotensin I (AT1), and Cytochrome c (CytC).
Main Results:
- Compound 2 showed lower reactivity with DNA compared to cisplatin (DDP).
- Compounds 1 and 2 exhibited increased reactivity towards peptides and proteins relative to DDP and oxaliplatin (OxPt).
- Platination sites on biomolecules were successfully identified.
Conclusions:
- Novel platinum(II) complexes may preferentially target peptides and proteins over DNA.
- This altered reactivity suggests a new mechanism of action for platinum-based anticancer agents.
- These findings support the development of alternative platinum therapeutics to address limitations of existing drugs.
More Related Videos
11:14Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
08:46Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
Published on: April 21, 2022
Related Concept Videos
Structural Isomerism
Isomers are different chemical species that have the same chemical formula. Structural isomerism of coordination compounds can be divided into two subcategories, the linkage isomers and coordination-sphere isomers.
Linkage isomers occur when the coordination compound contains a ligand that can bind to the transition metal center through two different atoms. For example, the CN− ligand can bind through the carbon atom or through the nitrogen atom. Similarly, SCN− can be...
Valence Bond Theory
Stereoisomerism
Isomers are different chemical species that have the same chemical formula.
Transition metal complexes often exist as geometric isomers, in which the same atoms are connected through the same types of bonds but with differences in their orientation in space. Coordination complexes with two different ligands in the cis and trans positions from a ligand of interest form isomers. For example, the octahedral [Co(NH3)4Cl2]+ ion has two isomers (Figure 1) In the cis...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Properties of Transition Metals
Phase II Reactions: Miscellaneous Conjugation Reactions
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...